Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Blast Crisis 1

Interventions

Rituximab 30Cyclophosphamide 18fludarabine phosphate 14Filgrastim 12Mycophenolic Acid 11Antilymphocyte Serum 11Cyclosporine 10Whole-Body Irradiation 9Bortezomib 9Tacrolimus 8Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Methotrexate 6Lenalidomide 6Cord Blood Stem Cell Transplantation 6Busulfan 6Granulocyte Colony-Stimulating Factor 5venetoclax 4tanespimycin 4Polymerase Chain Reaction 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Bendamustine Hydrochloride 4ublituximab 3thymoglobulin 3pembrolizumab 3ibritumomab tiuxetan 3fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell, Marginal Zone × Biological Therapy × Clear all
NCT00265928 2008-01-28

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡